TREND-HD - A Trial of Ethyl-EPA (Miraxion™) in Treating Mild to Moderate Huntington's Disease

Recruiting in Palo Alto (17 mi)

+40 other locations

Overseen by Ira Shoulson, MD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 3

Waitlist Available

Sponsor: Amarin Neuroscience Ltd

No Placebo Group

Pivotal Trial (Near Approval)

Prior Safety Data

Trial Summary

What is the purpose of this trial?

This study is designed to determine the effect of 2 gram/day of ethyl-EPA on motor (movement) signs and symptoms of Huntington disease.

Research Team

Christopher Ross, MD, PhD

Principal Investigator

Huntington Study Group/Johns Hopkins University School of Medicine

Blair Leavitt, MD

Principal Investigator

Huntington Study Group/University of British Columbia

Ira Shoulson, MD

Principal Investigator

Huntington Study Group/University of Rochester

Eligibility Criteria

Inclusion Criteria

Ambulatory, not requiring skilled nursing care (total functional capacity [TFC] greater than or equal to 7)

Chorea score of at least 2 in one extremity (UHDRS)

Maximal dystonia less than or equal to 2 and maximal bradykinesia less than or equal to 2

Treatment Details

Interventions

• Ethyl-EPA (Miraxion™) (Omega-3 Fatty Acid)

Find a Clinic Near You

Research Locations Nearby Select from list below to view details:

Mayo Clinic Arizona Scottsdale, AZ

Institute of Neurodegenerative Disorders New Haven, CT

University of Virginia Charlottesville, VA

University of Chicago Chicago, IL

More Trial Locations

Who Is Running the Clinical Trial?

Amarin Neuroscience Ltd

Lead Sponsor

Trials

1

Patients Recruited

300+

Huntington Study Group

Collaborator

Trials

15

Patients Recruited

9,400+